CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
CRISPR Therapeutics (Nasdaq: CRSP) celebrates the recognition of co-founder Professor Emmanuelle Charpentier, awarded the 2020 Nobel Prize in Chemistry for her contributions to the CRISPR/Cas9 technology. This honor reflects the significant impact of CRISPR research on gene-based therapies for serious diseases. CRISPR Therapeutics, leveraging this technology, aims to develop transformative medicines across various disease areas, notably in oncology and rare diseases. The company remains committed to advancing gene editing innovations amid the growing importance of genetic research.
- Nobel Prize awarded to co-founder Emmanuelle Charpentier highlights company's innovative position in gene editing.
- Recognition may enhance CRISPR Therapeutics' reputation and attract potential partnerships and investments.
- The company continues to develop transformative gene-based therapies using CRISPR/Cas9 technology.
- None.
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced Professor Emmanuelle Charpentier, CRISPR Therapeutics’ co-founder, has been awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system. Professor Charpentier co-founded CRISPR Therapeutics together with Rodger Novak and Shaun Foy. She is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University, Berlin, Germany. The prize was also awarded to Jennifer Doudna, Professor of Molecular and Cell Biology and Professor of Chemistry at the University of California, Berkeley and Investigator of the Howard Hughes Medical Institute.
“The entire CRISPR Therapeutics team would like to extend our heartfelt congratulations to Professor Emmanuelle Charpentier on becoming a Nobel Laureate,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “Professor Charpentier’s fundamental contribution to the discovery of CRISPR/Cas9 has laid the foundation for our work here at CRISPR Therapeutics, which is focused on developing transformative gene-based medicines with the potential to cure serious human diseases. We are incredibly proud and applaud her for the prestigious recognition she has received for her pioneering work.”
“Receiving the prestigious Nobel Prize, the highest distinction in science, is an extraordinary honor. I am very grateful and truly moved to receive this recognition for our work on the CRISPR/Cas9 system,” said Professor Emmanuelle Charpentier. “My thoughts go to my former lab members who have contributed significantly to the deciphering of the CRISPR/Cas9 mechanism in bacteria. This award obviously underscores the importance and relevance of fundamental research in the field of microbiology. I am truly amazed at the speed at which CRISPR research and applications in so many diverse areas of the life sciences have developed in recent years,” explained Emmanuelle Charpentier. “My most sincere acknowledgments to Rodger Novak, Samarth Kulkarni, the executive team, scientists and all members of CRISPR Therapeutics for their efforts and commitment to further develop the CRISPR/Cas9 technology as gene-based medicines to treat serious human diseases.”
In the announcement from the Royal Swedish Academy of Sciences, Professor Claes Gustafsson, Chair of the Nobel Committee for Chemistry commented on Professor Charpentier and Professor Doudna’s groundbreaking work: “There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science but also resulted in innovative crops and will lead to groundbreaking new medical treatments.” He added: “The enormous power of this technology means that we need to use it with great care. But it’s equally clear that this is a technology and method that will provide humankind with great opportunities.”
About Emmanuelle Charpentier
Emmanuelle Charpentier is considered a world-leading expert in regulatory mechanisms underlying processes of infection and immunity in bacterial pathogens. She is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University, Berlin, Germany. She co-founded CRISPR Therapeutics together with Rodger Novak and Shaun Foy.
Prior to her current appointments and until 2017, Emmanuelle Charpentier was Associate Professor at the Laboratory for Molecular Infection Medicine Sweden (MIMS, within the Nordic EMBL Partnership for Molecular Medicine) and visiting Professor at the Umeå Centre for Microbial Research (UCMR), Umeå University, Sweden, where she habilitated in Medical Microbiology in 2013. She was also Alexander von Humboldt Professor and Head of Department at the Helmholtz Centre for Infection Research in Braunschweig and Professor at the Hannover Medical School, Germany.
Emmanuelle Charpentier studied biochemistry, genetics and microbiology at the University Pierre and Marie-Curie (now Sorbonne University) in Paris, where she received her Ph.D. in microbiology for her research performed at the Pasteur Institute. Following her studies in France, she spent more than five years working in the U.S., where she held research associate positions in New York at the Rockefeller University, New York University Langone Medical Center and Skirball Institute of Biomolecular Medicine, and in Memphis, TN at the St. Jude Children’s Research Hospital. In 2002, she moved back to Europe to lead her first independent research group as Guest, Assistant and Associate Professor at the Max F. Perutz Laboratories (now Max Perutz Labs), University of Vienna, Austria where she habilitated in Microbiology in 2006.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Forward-Looking Statement
This press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations about the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: that the outcomes for each of CRISPR Therapeutics’ planned clinical trials and studies may not be favorable; that one or more of CRISPR Therapeutics’ internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics’ most recent annual report on Form 10-K, quarterly report on Form 10-Q and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law
CRISPR THERAPEUTICS® word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
CRISPR Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
CRISPR Media Contact:
Rachel Eides
WCG on behalf of CRISPR
+1 617-337-4167
reides@wcgworld.com
FAQ
What recent accolade did CRISPR Therapeutics co-founder receive?
How does the Nobel Prize affect CRISPR Therapeutics' stock?
What technology is at the core of CRISPR Therapeutics' work?
What areas of disease is CRISPR Therapeutics targeting?
